Pharmacy and Therapeutics (P & T) committees undertake policy, regulatory and educational activities to promote rational use of medicines in their institutions with the aim of improving the quality of health and economic outcomes at these institutions.
Formulary management is an important part of the P & T committees'activities and making drug choices is one of the committees'most difficult tasks.
The 3 types of information most commonly identified by P & T committees as necessary for making drug choices are effectiveness, safety and cost data ; usually in this order of importance.
There is some evidence, however, that safety data are not considered by all committees when they make decisions about adding a new drug to a formulary.
The role of adverse drug reaction (ADR) data in formulary decision-making (for registered drugs) occurs at several levels.
First, ADR data obtained from pre-marketing studies of the drug are important and enable the committee to make an assessment of the risk of toxicity that should be anticipated for the drug.
However, the limited nature of this information makes an absolute assessment impossible.
Secondly, comparative safety information is necessary when deciding the place in therapy of a particular drug.
Weighing up the comparative risks and benefits is a complex task which is a routine activity for most P & T committees whatever level of sophistication is applied. (...)
Mots-clés Pascal : Médicament, Recommandation, Utilisation, Prescription médicale, Choix, Toxicité, Analyse coût, Pharmacovigilance, Australie, Océanie
Mots-clés Pascal anglais : Drug, Recommendation, Use, Medical prescription, Choice, Toxicity, Cost analysis, Pharmacovigilance, Australia, Oceania
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 98-0202716
Code Inist : 002B02U10. Création : 11/09/1998.